Monday, October 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 18, 2026

JPMorgan has stark message on Qualcomm stock

View original at finance.yahoo.com
JPMorgan has stark message on Qualcomm stock JPMorgan is becoming more cautious on QUALCOMM Incorporated (QCOM) ahead of its upcoming earnings report, citing rising pressure in its core handset business…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Meaningful near-term downside risk with no clear event likely to improve the outlook for Qualcomm

    60% confidence

  • QCT revenue expected to decline 22% in calendar 2026

    60% confidence

  • Fiscal Q2 2026 non-GAAP EPS guidance of $2.45 to $2.65

    60% confidence

  • Rising pressure in Qualcomm's core handset business with newer growth areas not yet large enough to offset weakness

    60% confidence

  • Qualcomm's stock may not be cheap relative to normalized earnings power if handset weakness persists

    60% confidence

  • Fiscal Q2 2026 revenue guidance of $10.2 billion to $11.0 billion

    60% confidence

  • QCT EBT margin guidance of 26-28% for fiscal Q2 2026, down from 31% previously

    60% confidence

Data points we hold from this source

Qualcomm Incorporated · price target140 USD
Qualcomm Incorporated · previous price target185 USD
Qualcomm Incorporated · eps guidance low2.45 USD
Qualcomm Incorporated · eps guidance high2.65 USD
Qualcomm Incorporated · eps3.50 USD
Qualcomm Incorporated · revenue guidance high11.0 USD
Qualcomm Incorporated · revenue guidance low10.2 USD
Qualcomm Incorporated · consensus revenue12.21 USD
Qualcomm Incorporated · consensus eps3.39 USD

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com
JPMorgan has stark message on Qualcomm stock — Source | Via News | Via News